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Abstract 
Background: ACTION, a 24-week, prospective, randomized, parallel-group, double-blind study in patients 
with severe Alzheimer’s disease (AD), demonstrated significant efficacy of 13.3 mg/24 h versus 4.6 mg/24 h 
rivastigmine patch on the Severe Impairment Battery (SIB) and Alzheimer’s Disease Cooperative Study–
Activities of Daily Living scale–Severe Impairment Version (ADCS-ADL-SIV). Overall, 61% of the study 
population received ≥1 dose of concomitant memantine, regardless of dose or duration. This retrospective 
analysis investigated effects of concomitant memantine on the efficacy, safety and tolerability of 13.3 mg/24 h 
versus 4.6 mg/24 h rivastigmine patch. 
Methods: Patients were stratified according to whether or not they received at least one dose of concomitant 
memantine during the double-blind phase. Changes from baseline on the SIB and ADCS-ADL-SIV were 
compared using analysis of covariance (ANCOVA) with treatment, pooled center, memantine usage and 
treatment-by-memantine as factors, and baseline as a covariate. Safety and tolerability were assessed.  
Results: Memantine-treated patients were younger than those not receiving memantine (mean 75.9 and 78.8 
years, respectively), with a lower screening Mini-Mental State Examination (8.6 and 9.2, respectively). 
ANCOVA confirmed there was no significant interaction (p>0.1) between study treatment and memantine use 
on the SIB or ADCS-ADL-SIV. The incidence of adverse events was: 71.4%, 13.3 mg/24 h patch with 
memantine; 79.7%, 13.3 mg/24 h patch alone; 74.7%, 4.6 mg/24 h patch with memantine; and 71.1%, 4.6 mg/24 
h patch alone.  
Conclusions: These data suggest benefit of 13.3 mg/24 h versus 4.6 mg/24 h rivastigmine patch, regardless of 
concomitant memantine use. The incidence of adverse events with high-dose patch was similar in memantine-
treated patients and those not receiving memantine. 
Key words: ACTION study, high-dose, memantine, rivastigmine; severe Alzheimer’s disease; transdermal 
patch 
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Introduction 
Three cholinesterase inhibitors (ChEIs), rivastigmine, donepezil and galantamine, are approved in the USA for 
the treatment of mild-to-moderate Alzheimer’s disease (AD) [1-4]. All three are available in oral formulations 
[1, 3, 4]; rivastigmine is the only ChEI also approved for transdermal delivery, via a patch [2]. As well as mild-
to-moderate disease stages, rivastigmine transdermal patch is indicated for severe AD [2]. Oral donepezil is also 
indicated for moderate-to-severe AD [3], along with the N-methyl-D-aspartate (NMDA) receptor antagonist, 
memantine [5].  
Based on memantine’s alternative mechanism of action, there is a rationale for considering memantine as an 
add-on therapy to ChEIs in patients with moderate-to-severe AD. However, despite some positive studies in 
patients with moderate-to-severe AD, the benefits of combination therapy have yet to be robustly demonstrated 
[6]. Post-hoc meta-analyses of data from two 24-week, randomized, double-blind, placebo-controlled trials [7, 
8] reported that combination therapy with donepezil (10 mg/day) and memantine (20 mg/day) was associated
with enhanced efficacy, without marked impact on safety and tolerability, compared with donepezil alone, in 
patients with moderate or moderate-to-severe AD [9]. However, a 52-week, double-blind, placebo-controlled 
study reported no significant benefit of adding memantine (20 mg/day) to donepezil (10 mg/day) [10]. 
Furthermore, concomitant memantine (up to 20 mg/day) use was not found to have any impact on the efficacy 
of high-dose 23 mg/day versus 10 mg/day donepezil in a post-hoc analysis of a clinical study in patients with 
moderate-to-severe AD [11]. In this study, the incidence of treatment-emergent adverse events (AEs) was higher 
with 23 mg/day donepezil with memantine (80.7%) compared with 23 mg/day donepezil without memantine 
(69.7%) [11]. 
The ACTivities of daily living and cognitION (ACTION) study was a 24-week, randomized, double-blind 
comparison of 13.3 mg/24 h and 4.6 mg/24 h rivastigmine patch in patients with severe AD [12, 13]. In this 
study, the high-dose (13.3 mg/24 h) rivastigmine patch showed significantly superior efficacy compared with 
the low-dose (4.6 mg/24 h) rivastigmine patch on both co-primary endpoints, the Severe Impairment Battery 
(SIB) and the Alzheimer’s Disease Cooperative Study–Activities of Daily Living scale–Severe Impairment 
Version (ADCS-ADL-SIV) [13]. Given the advanced disease stage of the study population, patients were 
permitted to use concomitant memantine during the double-blind phase, provided they had been receiving a 
stable dose for at least 3 months prior to the screening visit [13]. The objective of the current post-hoc analysis 
of the ACTION study was to investigate the efficacy, safety and tolerability of the high-dose 13.3 mg/24 h 
versus the low-dose 4.6 mg/24 h rivastigmine patch in patients with severe AD stratified according to their use 
of concomitant memantine (up to 20 mg/day) during double-blind treatment. 
Material and Methods  
Study Design and Patients 
This was a retrospective post-hoc analysis of the 24-week, prospective, randomized, double-blind, double-
dummy, multicenter, US-based, ACTION study (ClinicalTrials.gov Identifier: NCT00948766) [12, 13].  
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Detailed methodology of the ACTION study has been published previously [12, 13]. Briefly, patients were male 
or female, aged ≥50 years, with probable AD (original 1984 National Institute of Neurological and 
Communicative Disorders and Stroke and AD and Related Disorders Association criteria) [14], and a Mini-
Mental State Examination (MMSE) [15] score of 3–12, inclusive. Patients were excluded if they had received 
ChEIs and/or other approved treatments for AD during the previous 2 weeks, with the exception of stable 
memantine if taken for at least 3 months prior to screening. Eligible patients were randomized in a 1:1 ratio to 
receive 13.3 mg/24 h or 4.6 mg/24 h rivastigmine patch for 24 weeks. Co-primary outcome measures were the 
change from baseline at Week 24 on the SIB [16] and the ADCS-ADL-SIV [17]. Safety assessments included 
the incidence of AEs, serious AEs (SAEs), and discontinuations due to AEs or SAEs. 
The ACTION study was conducted in accordance with Good Clinical Practice and the ethical principles of the 
Declaration of Helsinki. All patients, or their legally authorized representative, provided written informed 
consent prior to participating. 
Statistical Analysis 
In the current analysis, patients randomized to 13.3 mg/24 h or 4.6 mg/24 h rivastigmine patch were stratified 
according to whether or not they received at least one dose of concomitant memantine (up to 20 mg/day) during 
the double-blind phase.  
The least-squares mean (LSM) change from baseline at Weeks 8, 16 and 24 (Week 24 being the primary 
endpoint) on the SIB and ADCS-ADL-SIV were estimated for each subgroup (13.3 mg/24 h rivastigmine patch 
with memantine, 4.6 mg/24 h rivastigmine patch with memantine, 13.3 mg/24 h rivastigmine patch without 
memantine, and 4.6 mg/24 h rivastigmine patch without memantine). The efficacy of 13.3 mg/24 h versus 4.6 
mg/24 h rivastigmine patch in patients who received concomitant memantine, and 13.3 mg/24 h versus 4.6 
mg/24 h rivastigmine patch in patients not treated with memantine was compared using analysis of covariance 
(ANCOVA) with treatment, pooled center, memantine usage and treatment-by-memantine as factors, and the 
respective baseline as a covariate. To address imbalance in between-group patient demographics and 
characteristics additional between-group comparisons using the same model were performed for completeness. 
Efficacy analyses were based on the Modified Full Analysis Set (MFAS), which included all randomized 
patients who received at least one dose of study medication and had at least one post-baseline measurement, 
with missing data imputed using the Last Observation Carried Forward (LOCF) approach. 
Sensitivity analyses for the SIB and ADCS-ADL-SIV were conducted using a Mixed-Effect Model Repeated 
Measure (MMRM) and pattern mixture models. MMRM analyses were based on a repeated measures 
ANCOVA model with treatment, pooled center, visit, memantine usage, memantine usage-by-treatment, 
treatment-by-visit, visit-by-memantine usage and visit-by-memantine usage-by-treatment as factors, and the 
respective baseline total score as a covariate, assuming an unstructured within-subject covariance matrix. Pattern 
mixture model analyses were based on a repeated measures ANCOVA model with treatment, visit, pooled 
center, memantine usage, dropout, memantine usage-by-treatment, treatment-by-visit, visit-by-memantine 
usage, dropout-by-memantine usage, treatment-by-dropout, visit-by-memantine usage-by-treatment and 
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dropout-by-memantine usage-by-treatment as factors, and the respective baseline total score as a covariate, 
assuming an unstructured within-subject covariance matrix. 
Safety evaluations included the incidence of AEs and SAEs in each subgroup. The safety set included all 
patients who received at least one dose of study medication and had at least one safety assessment post-baseline. 
Results 
Participants  
Of 716 patients randomized to 13.3 mg/24 h or 4.6 mg/24 h rivastigmine patch, 435 (60.8%; 13.3 mg/24 h 
rivastigmine patch, N=217; 4.6 mg/24 h rivastigmine patch, N=218) received concomitant memantine, 
regardless of dose or treatment duration.  
The study was completed by a similar proportion of patients who received 13.3 mg/24 h rivastigmine patch and 
memantine (66.8%), 4.6 mg/24 h rivastigmine patch and memantine (65.1%), 13.3 mg/24 h rivastigmine patch 
without memantine (60.4%) and 4.6 mg/24 h rivastigmine patch without memantine (64.8%). In all subgroups, 
AEs (13.3 mg/24 h rivastigmine patch and memantine, 18.0%; 4.6 mg/24 h rivastigmine patch and memantine, 
12.4%; 13.3 mg/24 h rivastigmine patch without memantine, 24.5%; and 4.6 mg/24 h rivastigmine patch 
without memantine, 16.9%) and withdrawal of consent (7.4%, 12.4%, 7.9% and 13.4%, respectively) were the 
primary reasons for discontinuation.  
Baseline demographics and characteristics were generally comparable, with the exception that memantine-
treated patients tended to be slightly younger, with a longer time since AD diagnosis compared with those who 
did not receive memantine (Table 1).  
Table 1. Patient demographics and background characteristics by treatment group and concomitant memantine 
use (randomized set).  
Patients with  
concomitant memantine use 
Patients without  
concomitant memantine use 
13.3 mg/24 h 
rivastigmine 
patch 
N=217 
4.6 mg/24 h 
rivastigmine 
patch 
N=218 
Overall 
N=435 
13.3 mg/24 h 
rivastigmine 
patch 
N=139 
4.6 mg/24 h 
rivastigmine 
patch 
N=142 
Overall 
N=281 
Mean (SD) age, years 76.3 (8.6) 75.5 (9.0) 75.9 (8.8) 79.6 (8.5) 78.0 (9.8) 78.8 (9.2) 
Gender, % female 62.7 64.7 63.7 65.5 65.5 65.5 
Race, % 
Caucasian 
Black 
Other 
88.5 
8.3 
3.2 
89.4 
5.0 
5.5 
89.0 
6.7 
4.4 
82.0 
7.2 
10.8 
87.3 
5.6 
7.0 
84.7 
6.4 
8.9 
Mean (SD) weight, kg 70.4 (14.8) 70.5 (15.3)* 70.4 (15.0)† 67.1 (14.7)‡ 67.9 (16.6) 67.5 (15.7)§ 
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MMSE at screening 
Mean (SD) 
Range 
8.7 (2.8) 
3.0–13.0 
8.6 (3.0) 
3.0–19.0 
8.6 (2.9) 
3.0–19.0 
9.1 (2.9) 
3.0–12.0 
9.2 (2.9) 
3.0–12.0 
9.2 (2.9) 
3.0–12.0 
Mean (SD) baseline 
SIB score  
66.4 (22.3)¶ 65.8 (23.1)¶ 66.1 (22.7)‖ 73.2 (19.6)** 71.3 (22.2) 72.2 (20.9)†† 
Mean (SD) baseline 
ADCS-ADL-SIV score 
29.9 (11.0)‡‡ 28.8 (11.3)§§ 29.4 (11.1)¶¶ 29.4 (11.6)** 29.4 (12.9)‡ 29.4 (12.2)‖‖ 
Mean (SD) years since 
diagnosis of AD 
4.6 (2.6) 4.4 (2.6) 4.5 (2.6) 3.6 (2.8) 3.4 (2.6) 3.5 (2.7) 
Mean (SD) years since 
diagnosis of severe 
dementia 
1.3 (1.9) 1.4 (1.8) 1.3 (1.8) 1.1 (1.9) 0.9 (1.2)*** 1.0 (1.6)§ 
Living situation, % 
Home 
Assisted living 
facility 
Other 
89.4 
8.3 
2.3 
88.1 
10.1 
1.8 
88.7 
9.2 
2.1 
92.1 
6.5 
1.4 
88.0 
9.2 
2.8 
90.0 
7.8 
2.1 
AD, Alzheimer’s disease; ADCS-ADL-SIV, Alzheimer’s Disease Cooperative Study–Activities of Daily Living 
scale–Severe Impairment Version; MMSE, Mini-Mental State Examination; N, number of patients in the 
population; n, number of patients reporting with available data; SD, standard deviation; SIB, Severe Impairment 
Battery. *n=217; †n=434; ‡n=138; §n=280; ¶n=216; ‖n=432; **n=137; ††n=279; ‡‡n=212; §§n=205; ¶¶n=417; 
‖‖n=275; ***n=141. 
Efficacy Outcomes  
Numerically less decline was observed on the SIB and ADCS-ADL-SIV with 13.3 mg/24 h versus 4.6 mg/24 h 
rivastigmine patch, regardless of concomitant memantine use. The high-dose 13.3 mg/24 h rivastigmine patch 
was associated with significantly greater efficacy versus the low-dose 4.6 mg/24 h rivastigmine patch on the SIB 
at Weeks 16 and 24, both in patients receiving concomitant memantine (LSM difference [95% CI]: 3.6 [1.0, 
6.3]), p=0.01; and 3.8 [1.1, 6.5], p=0.01, respectively) and patients who did not receive concomitant memantine 
(6.9 [3.5, 10.2], p<0.0001; and 6.6 (3.3, 10.0], p=0.0001, respectively; Fig. 1). On the ADCS-ADL-SIV, 
significantly less decline (LSM difference [95% CI]: 1.4 [0.0, 2.8], p=0.04) was observed at Week 24 with 13.3 
mg/24 h versus 4.6 mg/24 h rivastigmine patch in patients who received concomitant memantine (Fig. 2).  
Overall, ANCOVA analysis confirmed that there was no significant interaction (p>0.1) between treatment and 
memantine use at any time point on the SIB (Week 8, p=0.95; Week 16, p=0.14; Week 24, p=0.20) or ADCS-
ADL-SIV (Week 8, p=0.96; Week 16, p=0.68; Week 24, p=0.69). These findings were supported by the 
sensitivity (MMRM and pattern mixture model) analyses (SIB: p=0.15 and p=0.53, respectively; ADCS-ADL-
SIV, p=0.88 and p=0.49, respectively). 
7 
Based on the observed differences at baseline between memantine-treated patients, and patients not receiving 
memantine, additional ANCOVA analyses were performed, which included baseline MMSE score, age and time 
since diagnosis of AD as additional covariates. In general, the findings obtained with this model were similar to 
those obtained with the original ANCOVA model. 
Safety and Tolerability  
All patients (i.e. 100%) in the 4.6 mg/24 h rivastigmine patch group (regardless of memantine use), 84.8% of 
patients randomized to 13.3 mg/24 h rivastigmine patch who received memantine and 85.5% of patients 
randomized to 13.3 mg/24 h rivastigmine patch who did not receive memantine were treated with the target dose 
at the end of the study. The mean (standard deviation [SD]) duration of exposure to rivastigmine (in weeks) was 
similar in all subgroups (13.3 mg/24 h rivastigmine patch and memantine, 19.8 [8.0]; 4.6 mg/24 h rivastigmine 
patch and memantine, 20.1 [7.4]; 13.3 mg/24 h rivastigmine patch without memantine, 19.4 [7.8]; 4.6 mg/24 h 
rivastigmine patch without memantine, 20.0 [8.0]). 
The incidence of AEs was similar in all subgroups (Table 2). The most common AEs reported by patients who 
received 13.3 mg/24 h rivastigmine patch and memantine were application site erythema (13.4%), agitation 
(12.9%), application site dermatitis (9.2%) and fall (9.2%); in those who received 13.3 mg/24 h rivastigmine 
patch without memantine, AEs were most commonly urinary tract infection (13.0%), application site erythema 
(13.0%) and agitation (9.4%). In patients randomized to 4.6 mg/24 h rivastigmine patch who received 
memantine, the most common AEs were agitation (13.8%), application site erythema (12.9%) and urinary tract 
infection (8.8%); and in those who received 4.6 mg/24 h rivastigmine patch without memantine, AEs were most 
commonly agitation (14.8%), urinary tract infection (10.6%) and application site dermatitis (10.6%). 
The incidence of SAEs was similar in all subgroups (Table 2). In both the 13.3 mg/24 h and 4.6 mg/24 h patch 
groups, the proportion of patients who discontinued due to AEs or SAEs was slightly higher in patients who did 
not receive concomitant memantine compared with those who received memantine.  
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Table 2. Discontinuation due to AEs and SAEs, and most frequent AEs* by treatment group and concomitant 
memantine use (safety set).  
Patients with  
concomitant memantine use 
Patients without concomitant 
memantine use 
13.3 mg/24 h 
rivastigmine 
patch 
N=217 
n (%) 
4.6 mg/24 h 
rivastigmine 
patch 
N=217 
n (%) 
Overall 
N=434 
n (%) 
13.3 mg/24 h 
rivastigmine  
patch 
N=138 
n (%) 
4.6 mg/24 h 
rivastigmine 
patch 
N=142 
n (%) 
Overall 
N=280 
n (%) 
Any AE 155 (71.4) 162 (74.7) 317 (73.0) 110 (79.7) 101 (71.1) 211 (75.4) 
Any SAE 32 (14.7) 26 (12.0) 58 (13.4) 21 (15.2) 23 (16.2) 44 (15.7) 
Discontinuation 
due to AE 
40 (18.4) 28 (12.9) 68 (15.7) 33 (23.9) 24 (16.9) 57 (20.4) 
Discontinuation 
due to SAE 
16 (7.4) 6 (2.8) 22 (5.1) 13 (9.4) 10 (7.0) 23 (8.2) 
Most common AEs (preferred term) 
Application site 
erythema 
29 (13.4) 28 (12.9) 57 (13.1) 18 (13.0) 14 (9.9) 32 (11.4) 
Agitation 28 (12.9) 30 (13.8) 58 (13.4) 13 (9.4) 21 (14.8) 34 (12.1) 
Application site 
dermatitis 
20 (9.2) 18 (8.3) 38 (8.8) 7 (5.1) 15 (10.6) 22 (7.9) 
Fall 20 (9.2) 16 (7.4) 36 (8.3) 7 (5.1) 5 (3.5) 12 (4.3) 
Insomnia 16 (7.4) 10 (4.6) 26 (6.0) 9 (6.5) 5 (3.5) 14 (5.0) 
Vomiting 16 (7.4) 6 (2.8) 22 (5.1) 9 (6.5) 3 (2.1) 12 (4.3) 
Nausea 15 (6.9) 5 (2.3) 20 (4.6) 7 (5.1) 5 (3.5) 12 (4.3) 
Weight decreased 15 (6.9) 8 (3.7) 23 (5.3) 8 (5.8) 3 (2.1) 11 (3.9) 
Diarrhea 12 (5.5) 9 (4.1) 21 (4.8) 11 (8.0) 10 (7.0) 21 (7.5) 
Depression 11 (5.1) 9 (4.1) 20 (4.6) 6 (4.3) 6 (4.2) 12 (4.3) 
Urinary tract 
infection 
11 (5.1) 19 (8.8) 30 (6.9) 18 (13.0) 15 (10.6) 33 (11.8) 
Anxiety 10 (4.6) 11 (5.1) 21 (4.8) 6 (4.3) 5 (3.5) 11 (3.9) 
Decreased 
appetite 
10 (4.6) 3 (1.4) 13 (3.0) 7 (5.1) 2 (1.4) 9 (3.2) 
Edema peripheral 5 (2.3) 12 (5.5) 17 (3.9) 3 (2.2) 0 (0.0) 3 (1.1) 
Somnolence 5 (2.3) 5 (2.3) 10 (2.3) 7 (5.1) 4 (2.8) 11 (3.9) 
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AE, adverse event; N, number of patients in the population; n, number of patients reporting AE; SAE, serious 
adverse event. *Only AEs occurring in ≥5% of patients in the 13.3 mg/24 h or 4.6 mg/24 h rivastigmine patch 
group are shown. A patient with multiple occurrences of an AE was counted only once in the AE category. AEs 
are presented by descending frequency in patients randomized to 13.3 mg/24 h rivastigmine patch who received 
concomitant memantine. 
Discussion 
The current retrospective analysis investigated the efficacy, safety and tolerability of high-dose (13.3 mg/24 h) 
rivastigmine patch versus low-dose (4.6 mg/24 h) rivastigmine patch in patients stratified according to their use 
of concomitant memantine during double-blind treatment. Given the advanced disease stage of the enrolled 
patient population (mean MMSE score at screening, 8.8) and the indication of memantine for moderate-to-
severe AD [5], it was not unexpected that 61% of this North American patient population received at least one 
dose of concomitant memantine during the study [13]. Based on our clinical experience, the proportion of 
patients in this study who received concomitant memantine is consistent with real-world clinical practice in the 
USA.  
Administering agents with distinct mechanisms of action, such as memantine (NMDA receptor antagonist) [5] 
and rivastigmine (ChEI) [1, 2] in combination may be associated with differential and/or additive effects. In 
addition to a potential class effect, rivastigmine is unique amongst the approved ChEIs, in that it is the only one 
to inhibit both acetylcholinesterase and butyrylcholinesterase (donepezil and galantamine are 
acetylcholinesterase-selective) [18]. In addition, although widely considered to be a symptomatic treatment, 
studies in rodents have provided evidence for positive effects of rivastigmine on neurodegeneration in the 
synapse [19, 20]. These mechanistic differences may have biological implications. Given that the efficacy of 
rivastigmine is dose-dependent and cholinergic deficits increase with disease severity [21, 22], it seems 
clinically relevant to investigate the combination of memantine and high-dose rivastigmine in patients with 
severe AD. Studies with high-dose rivastigmine are made possible via transdermal delivery, which provides 
access to higher doses than can be reached with oral formulations, due to improved tolerability [23]. To our 
knowledge, these were the first analyses to investigate the concomitant use of 13.3 mg/24 h rivastigmine patch 
and memantine in a population with severe AD.  
Supporting the primary efficacy findings from the ACTION study [13], superior efficacy was observed on the 
SIB with 13.3 mg/24 h versus 4.6 mg/24 h rivastigmine patch in patients who received concomitant memantine 
and those not receiving memantine. Significant between-group differences (13.3 mg/24 h versus 4.6 mg/24 h 
rivastigmine patch) were also observed at Week 24 on the ADCS-ADL-SIV in memantine-treated patients, and 
there was a numerical trend toward greater efficacy with the high-dose 13.3 mg/24 h rivastigmine patch in those 
not receiving memantine. The lack of statistical significance in the change from baseline at Week 24 on the 
ADCS-ADL-SIV between patients randomized to 13.3 mg/24 h versus 4.6 mg/24 h rivastigmine patch who did 
not receive memantine may have been due, in part, to the small sample size of this subpopulation. Overall, these 
analyses, based on the MFAS population with a LOCF imputation, and supportive MMRM and pattern mixture 
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model analyses, demonstrated there was no significant interaction between rivastigmine patch treatment and 
memantine use. 
With regard to safety, the current analyses suggest that, although there was a slightly higher incidence of AEs 
among 13.3 mg/24 h rivastigmine patch-treated patients who did not receive concomitant memantine compared 
with those who received memantine (79.7% versus 71.4%), the safety and tolerability profile of 13.3 mg/24 h 
rivastigmine patch was generally similar in both subpopulations.  
The current post-hoc analyses were intended to be hypothesis-forming, and this should be taken into 
consideration when interpreting the findings. The ACTION study was not powered to detect effects of 
memantine use on the efficacy, safety and tolerability of 13.3 mg/24 h versus 4.6 mg/24 h rivastigmine patch. 
Although the current analyses suggest there are no additive effects of concomitant treatment with memantine 
and rivastigmine, additional analyses would be required to confirm these findings. It should be noted that 
patients were not randomly allocated to memantine treatment; hence there were imbalances between the 
subpopulations with regard to their baseline characteristics, which may also have influenced findings. However, 
similar findings were obtained regardless of whether baseline MMSE score, age, and time since AD diagnosis 
were included as covariates in the statistical model, suggesting these factors do not have a marked impact on the 
observed results.  
The effect of concomitant memantine use on the efficacy, safety and tolerability of 9.5 mg/24 h rivastigmine 
patch in patients with mild-to-moderate AD has been previously investigated [24, 25]. An open-label study 
reported no marked differences in the safety or efficacy of combination therapy with 9.5 mg/24 h rivastigmine 
patch and memantine compared with 9.5 mg/24 h rivastigmine patch alone in patients with mild-to-moderate 
AD [24]. Furthermore, post-hoc analysis of a 25-week, randomized, open-label study reported a non-significant 
increase in the incidence of AEs in patients with mild-to-moderate AD treated with 9.5 mg/24 h rivastigmine 
patch plus memantine, compared with memantine alone (73.3% versus 67.5%) [25]. Overall, there were no 
significant differences in the efficacy of 9.5 mg/24 h rivastigmine patch between patients receiving memantine 
and patients not receiving memantine on the Clinical Global Impression of Change, or the MMSE; memantine-
treated patients demonstrated significantly greater deterioration on the ADCS-ADL scale compared with those 
not receiving memantine [25]. The 9.5 mg/24 h rivastigmine patch was not included in the current analysis, as 
although used during dose titration, it was not a randomized target dose in the ACTION study. During 
ACTION, the first study of rivastigmine patch in patients with severe AD, 4.6 mg/24 h patch was selected as a 
low-dose active comparator to fully investigate the efficacy, safety and tolerability of the high-dose 13.3 mg/24 
h patch in this patient population [13]. Further, large-scale, randomized, controlled clinical studies would be 
required to fully investigate the effect of memantine use on the efficacy, safety and tolerability of 13.3 mg/24 h 
rivastigmine patch (and other patch doses, i.e. 9.5 mg/24 h) in patients with severe AD.  
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Conclusion 
These data suggest high-dose 13.3 mg/24 h rivastigmine patch is associated with greater efficacy compared with 
4.6 mg/24 h rivastigmine patch on cognition and the ability to perform activities of daily living in patients with 
severe AD, regardless of whether or not the patient received concomitant memantine. In the USA, the high-dose 
13.3 mg/24 h rivastigmine transdermal patch can now be considered as a treatment option across all disease 
stages, from mild-to-moderate to severe AD [2]. Memantine may be considered as an add-on therapy in patients 
with moderate-to-severe disease [26], but does not appear to affect the efficacy, safety and tolerability of ChEI 
treatment. 
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Fig. (1). Least-squares mean change from baseline to Week 24 on the SIB (MFAS-LOCF). 
Comparison  
(+, with memantine; -, without memantine) 
Point estimate  
(difference LSM, Week 24) 
P-value 
13.3 mg/24 h  - 13.3 mg/24 h + 3.96 0.02 
13.3 mg/24 h - 4.6 mg/24 h - 6.64 0.0001 
13.3 mg/24 h - 4.6 mg/24 h + 7.74 <0.0001 
13.3 mg/24 h + 4.6 mg/24 h - 2.68 0.10 
13.3 mg/24 h + 4.6 mg/24 h + 3.78 0.01 
4.6 mg/24 h - 4.6 mg/24 h + 1.10 0.50 
LSM, least-squares mean; MFAS-LOCF, Modified Full Analysis Set with a Last Observation Carried Forward 
imputation; SIB, Severe Impairment Battery; SE, standard error. Error bars represent the SE of the LSM. 
*p<0.01 13.3 mg/24 h versus 4.6 mg/24 h rivastigmine patch. 13.3 mg/24 h patch without memantine, n=121–
122; 13.3 mg/24 h patch with memantine, n=189–191; 4.6 mg/24 h patch without memantine, n=123–124; 4.6 
mg/24 h patch with memantine, n=189–192. Change from baseline at Weeks 8, 16 and 24 shown (data points 
are staggered). 
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Fig. (2). Least-squares mean change from baseline to Week 24 on the ADCS-ADL-SIV (MFAS-LOCF).  
 
 
 
Comparison  
(+, with memantine; -, without memantine) 
Point estimate  
(difference LSM, Week 24) 
P-value 
13.3 mg/24 h  - 13.3 mg/24 h + 1.47 0.09 
13.3 mg/24 h - 4.6 mg/24 h - 0.97 0.27 
13.3 mg/24 h - 4.6 mg/24 h + 2.91 0.0007 
13.3 mg/24 h + 4.6 mg/24 h - -0.49 0.56 
13.3 mg/24 h + 4.6 mg/24 h + 1.44 0.04 
4.6 mg/24 h - 4.6 mg/24 h + 1.93 0.02 
 
ADCS-ADL-SIV, Alzheimer’s Disease Cooperative Study–Activities of Daily Living scale–Severe Impairment 
Version; LSM, least-squares means; MFAS-LOCF, Modified Full Analysis Set with a Last Observation Carried 
Forward imputation; SE, standard error. Error bars represent the SE of the LSM. *p<0.05 13.3 mg/24 h versus 
4.6 mg/24 h rivastigmine patch. 13.3 mg/24 h patch without memantine, n=122; 13.3 mg/24 h patch with 
memantine, n=186–188; 4.6 mg/24 h patch without memantine, n=119–121; 4.6 mg/24 h patch with memantine, 
n=181–182. Change from baseline at Weeks 8, 16 and 24 shown (data points are staggered). 
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